Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 3, 1997, Pages 192-197

  Rolinski, Boris ^a,b   Bogner, Johannes R ^a   Sadri, Ifna ^a   Wintergerst, Uwe ^b   Goebel, Frank D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Analysis; Blood CSF barrier; Central nervous system (CNS); Cerebrospinal fluid (CSF); Pharmacokinetics; Zidovudine (ZDV)

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR PUNCTURE; MALE; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; VIRUS INFECTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030843413     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199707010-00002     Document Type: Article

References (23)

1. Yarchoan R, Berg G, Brouwers P, et al. Response of human immunodeficiency virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1987;1:132-5.
2. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection [see comments]. N Engl J Med 1988;319:889-96.
3. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988;319:1573-8.
4. Portegies P, de Gans J, Lange JM, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment [see comments]. BMJ 1989;299:819-21. erratum BMJ 1989; 299:1141.
5. Tartaglione TA, Collier AC, Coombs RW, et al. Acquired immunodeficiency syndrome: cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Arch Neurol 1991;48:695-9. erratum Arch Neurol 1991;48:1238.
6. Gray F, Geny C, Dournon E, Fenelon F, Lionnet F, Gherardi R. Neuropathological evidence that zidovudine reduces incidence of HIV infection of brain [letter] [see comments]. Lancet 1991;337: 852-3.
7. Vago L, Castagna A, Lazzarin A, Trabattoni G, Cinque P, Costanzi G. Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Acquir Immune Defic Syndr 1993; 6:42-5.
8. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 1993;33:343-9.
9. Tozzi V, Narciso P, Galgani S, et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 1993;7:683-92.
10. Portegies P, Enting RH, de Gans J, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS 1993;7:669-75.
11. Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1990;323:1009-14.
12. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989;110:279-85.
13. Klecker RW Jr, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987;41:407-12.
14. Surbone A, Yarchoan R, McAtee N, et al. Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3′-azido-2′,3′-dideoxythymidine (azidothymidine or zidovudine) and acyclovir: a pilot study. Ann Intern Med 1988;108:534-40.
15. Yarchoan R, Thomas RV, Grafman J, et al. Long-term administration of 3′-azido-2′,3′-dideoxythymidine to patients with AIDS-related neurological disease. Ann Neurol 1988;23(Suppl):S82-7.
16. Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993;7:1581-7.
17. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
18. Good SS, Reynolds DJ, De Miranda P. Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J Chromatogr 1988;431:123-33.
19. Heinzel G, Woloszczak R, Thomann P. Topfit 2.0: pharmacoki-netic and pharmacodynamic data analysis system for the PC. Stuttgart, Germany: Gustav Fischer Verlag, 1993:25-66.
20. Blum MR, Liao SH, Good SS, de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988;85: 189-94.
21. Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. New York: Macmillan, 1990:10-11.
22. Zimmermann TP, Mahony WB, Prus KL. 3′-Azido-3′-deoxythymidine: an unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by non-faciliated diffusion. J Biol Chem 1987;262:5748-54.
23. Rolinski B, Wintergerst U, Matuschke A. et al. Evaluation of saliva as a specimen for monitoring zidovudine therapy in HIV-infected patients. AIDS 1991;5:885-8.